Research analysts at StockNews.com initiated coverage on shares of NanoViricides (NYSE:NNVC – Get Free Report) in a research note issued on Sunday. The firm set a “sell” rating on the stock.
NanoViricides Price Performance
NYSE NNVC opened at $1.56 on Friday. The company’s 50 day moving average is $1.38 and its 200-day moving average is $1.30. NanoViricides has a 12-month low of $1.04 and a 12-month high of $2.43. The firm has a market cap of $18.10 million, a P/E ratio of -2.64 and a beta of 1.15.
Institutional Trading of NanoViricides
Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in NanoViricides by 7.1% during the 3rd quarter. Vanguard Group Inc. now owns 458,072 shares of the company’s stock worth $792,000 after acquiring an additional 30,194 shares during the period. Renaissance Technologies LLC grew its stake in NanoViricides by 72.2% in the 1st quarter. Renaissance Technologies LLC now owns 76,800 shares of the company’s stock worth $161,000 after buying an additional 32,200 shares in the last quarter. Millennium Management LLC grew its stake in NanoViricides by 59.1% in the 4th quarter. Millennium Management LLC now owns 67,346 shares of the company’s stock worth $75,000 after buying an additional 25,012 shares in the last quarter. Two Sigma Investments LP purchased a new position in NanoViricides in the 3rd quarter worth approximately $59,000. Finally, UBS Group AG grew its stake in NanoViricides by 114.5% in the 1st quarter. UBS Group AG now owns 17,448 shares of the company’s stock worth $37,000 after buying an additional 9,314 shares in the last quarter. Institutional investors own 10.77% of the company’s stock.
NanoViricides Company Profile
NanoViricides, Inc is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R.
See Also
- Five stocks we like better than NanoViricides
- How to Use the MarketBeat Dividend Calculator
- 2 Stocks to Get You Ready for the Holiday Season
- How to Invest in Renewable Energy
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- How to Invest in Blockchain Stocks Step by Step
- MarketBeat Week in Review – 8/21 – 8/25
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
